The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Open accessAbstract
The transthyretin amyloidoses (ATTR) are invariably fatal diseases characterized by progressive neuropathy and/or cardiomyopathy. ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A–retinol-binding protein complex. Mutations within TTR that cause autosomal dominant forms of disease facilitate tetramer dissociation, monomer misfolding, and aggregation, although wild-type TTR can also form amyloid fibrils in elderly patients. Because tetramer dissociation is the rate-limiting step in TTR amyloidogenesis, targeted therapies have focused on small molecules that kinetically stabilize the tetramer, inhibiting TTR amyloid fibril formation. One such compound, tafamidis meglumine (Fx-1006A), has recently completed Phase II/III trials for the treatment of Transthyretin Type Familial Amyloid Polyneuropathy (TTR-FAP) and demonstrated a slowing of disease progression in patients heterozygous for the V30M TTR mutation. Herein we describe the molecular and structural basis of TTR tetramer stabilization by tafamidis. Tafamidis binds selectively and with negative cooperativity (K d s ∼2 nM and ∼200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically stabilizes TTR. Patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants, are also stabilized by tafamidis binding. The crystal structure of tafamidis-bound TTR suggests that binding stabilizes the weaker dimer-dimer interface against dissociation, the rate-limiting step of amyloidogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Protein Misfolding, Functional Amyloid, and Human Disease
Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,423
Amyloid pores from pathogenic mutations
Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., & Lansbury, P. T. (2002) · Nature · doi:10.1038/418291a · Cited by 1,289
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Self-citationBlake, C. C. F., Geisow, M. J., Oatley, S. J., Rérat, B., & Rérat, C. (1978) · Journal of Molecular Biology · doi:10.1016/0022-2836(78)90368-6 · Cited by 791
Fibril in senile systemic amyloidosis is derived from normal transthyretin.
Westermark, P., Sletten, K., Johansson, B., & Cornwell, G. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2843 · Cited by 696
Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
Colon, W., & Kelly, J. W. (1992) · Biochemistry · doi:10.1021/bi00151a036 · Cited by 573
Self-citationVariant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans
Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., & Buxbaum, J. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702133360703 · Cited by 554
Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
Hammarström, P., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2003) · Science · doi:10.1126/science.1079589 · Cited by 525
Self-citationThe Biological and Chemical Basis for Tissue-Selective Amyloid Disease
Sekijima, Y., Wiseman, R. L., Matteson, J., Hammarström, P., Miller, S. R., Sawkar, A. R., Balch, W. E., & Kelly, J. W. (2005) · Cell · doi:10.1016/j.cell.2005.01.018 · Cited by 488
Self-citationGutfreund, H. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)81192-b · Cited by 450
Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein
Monaco, H., Rizzi, M., & Coda, A. (1995) · Science · doi:10.1126/science.7754382 · Cited by 409
Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W., & Buxbaum, J. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400062101 · Cited by 392
Self-citationRational design of potent human transthyretin amyloid disease inhibitors.
Sacchettini, J. C., Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., & Kelly, J. W. (2000) · Nature Structural Biology · doi:10.1038/74082 · Cited by 379
Self-citationBinding and Linkage: Functional Chemistry of Biological Macromolecules
Wyman, J., & Gill, S. J. (1990) · Medical Entomology and Zoology · Cited by 368
Ng, B., Connors, L. H., Davidoff, R., Skinner, M., & Falk, R. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1425 · Cited by 367
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Self-citationDeposition of Transthyretin in Early Stages of Familial Amyloidotic Polyneuropathy
Mendes Sousa, M., Cardoso, I., Fernandes, R., Guimarães, A., & Saraiva, M. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63050-7 · Cited by 344
Transthyretin Aggregation under Partially Denaturing Conditions Is a Downhill Polymerization
Hurshman, A. R., White, J. T., Powers, E. T., & Kelly, J. W. (2004) · Biochemistry · doi:10.1021/bi049621l · Cited by 340
Self-citationJohnson, S. M., Wiseman, R. L., Sekijima, Y., Green, N. S., Adamski-Werner, S. L., & Kelly, J. W. (2005) · Accounts of Chemical Research · doi:10.1021/ar020073i · Cited by 303
Self-citationTrans -Suppression of Misfolding in an Amyloid Disease
Hammarström, P., Schneider, F., & Kelly, J. W. (2001) · Science · doi:10.1126/science.1062245 · Cited by 293
Self-citationSekijima, Y., Dendle, M. A., & Kelly, J. W. (2006) · Amyloid · doi:10.1080/13506120600960882 · Cited by 268
Self-citationA comparative analysis of 23 structures of the amyloidogenic protein transthyretin
Hörnberg, A., Eneqvist, T., Olofsson, A., Lundgren, E., & Sauer-Eriksson, A. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4078 · Cited by 239
Razavi, H., Palaninathan, S. K., Powers, E. T., Wiseman, R. L., Purkey, H. E., Mohamedmohaideen, N. N., Deechongkit, S., Chiang, K. P., Dendle, M. T. A., Sacchettini, J. C., et al. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200351179 · Cited by 232
Self-citationAdamski-Werner, S. L., Palaninathan, S. K., Sacchettini, J. C., & Kelly, J. W. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030347n · Cited by 230
Self-citationTransthyretin mutations in health and disease
João, M., & Saraiva, M. (1995) · Human Mutation · doi:10.1002/humu.1380050302 · Cited by 220
Miller, S. R., Sekijima, Y., & Kelly, J. W. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700059 · Cited by 198
Self-citationThe Pathway by Which the Tetrameric Protein Transthyretin Dissociates
Foss, T. R., Wiseman, R. L., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi051608t · Cited by 193
Self-citationWojtczak, A., Cody, V., Luft, J. R., & Pangborn, W. (1996) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996003046 · Cited by 188
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses
Connelly, S., Choi, S., Johnson, S. M., Kelly, J. W., & Wilson, I. A. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.12.009 · Cited by 176
Self-citationThyroid Hormone Transport Proteins
Bartalena, L., & ROBBINS, J. J. (1993) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30427-x · Cited by 167
Jiang, X., Buxbaum, J. N., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261419998 · Cited by 166
Self-citationPurkey, H. E., Palaninathan, S. K., Kent, K. C., Smith, C., Safe, S. H., Sacchettini, J. C., & Kelly, J. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.10.009 · Cited by 158
Self-citationA glimpse of a possible amyloidogenic intermediate of transthyretin.
Wemmer, D. E., Liu, K., Cho, H. S., Lashuel, H. A., & Kelly, J. W. (2000) · Nature Structural Biology · doi:10.1038/78980 · Cited by 150
Self-citationDiscovering transthyretin amyloid fibril inhibitors by limited screening
Baures, P. W., Peterson, S., & Kelly, J. W. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00130-8 · Cited by 141
Self-citationHurshman, A. R., Powers, E. T., & Kelly, J. W. (2008) · Biochemistry · doi:10.1021/bi800636q · Cited by 138
Self-citationJohnson, S. M., Connelly, S., Wilson, I. A., & Kelly, J. W. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0708735 · Cited by 136
Self-citationBaures, P. W., Oza, V. B., Peterson, S., & Kelly, J. W. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00066-8 · Cited by 135
Self-citationOza, V. B., Smith, C., Raman, P., Koepf, E. K., Lashuel, H. A., Petrassi, H. M., Chiang, K. P., Powers, E. T., Sachettinni, J., & Kelly, J. W. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010257n · Cited by 133
Self-citationFamilial amyloidotic polyneuropathy
Benson, M. D., & Roudebush, R. L. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90162-8 · Cited by 125
Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma
Purkey, H. E., Dorrell, M. I., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091431798 · Cited by 124
Self-citationOnly amyloidogenic intermediates of transthyretin induce apoptosis
Andersson, K., Olofsson, A., Nielsen, E. H., Svehag, S., & Lundgren, E. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00465-5 · Cited by 118
Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs
Bourgault, S., Choi, S., Buxbaum, J. N., Kelly, J. W., Price, J. L., & Reixach, N. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.133 · Cited by 115
Self-citationAutonomic dysfunction in familial amyloidotic polyneuropathy (FAP)
Ando, Y., & Suhr, O. B. (1998) · Amyloid · doi:10.3109/13506129809007303 · Cited by 108
Schneider, F., Hammarström, P., & Kelly, J. W. (2001) · Protein Science · doi:10.1110/ps.8901 · Cited by 105
Self-citationKinetic Stabilization of an Oligomeric Protein by a Single Ligand Binding Event
Wiseman, R. L., Johnson, S. M., Kelker, M. S., Foss, T. R., Wilson, I. A., & Kelly, J. W. (2005) · Journal of the American Chemical Society · doi:10.1021/ja042929f · Cited by 104
Self-citationJohnson, S. M., Connelly, S., Wilson, I. A., & Kelly, J. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801347s · Cited by 91
Self-citationGreen, N. S., Palaninathan, S. K., Sacchettini, J. C., & Kelly, J. W. (2003) · Journal of the American Chemical Society · doi:10.1021/ja030294z · Cited by 88
Self-citationStructure-Based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors
Petrassi, H. M., Klabunde, T., Sacchettini, J. C., & Kelly, J. W. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993309v · Cited by 84
Self-citationJohnson, S. M., Connelly, S., Wilson, I. A., & Kelly, J. W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800435s · Cited by 81
Self-citationSynthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors
Oza, V. B., Petrassi, H. M., Purkey, H. E., & Kelly, J. W. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00696-9 · Cited by 78
Self-citationHammarström, P., Jiang, X., Deechongkit, S., et al. (2001) · Biochemistry · doi:10.1021/bi010673+ · Cited by 75
Comparative Stability and Clearance of [Met30]Transthyretin and [Met119]Transthyretin
Alves, I. L., Hays, M. T., & Saraiva, M. J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00662.x · Cited by 74
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Merkies, I. S. J. (2013) · Neurology · doi:10.1212/01.wnl.0000429338.33391.87 · Cited by 72
Choi, S., Reixach, N., Connelly, S., Johnson, S. M., Wilson, I. A., & Kelly, J. W. (2009) · Journal of the American Chemical Society · doi:10.1021/ja908562q · Cited by 70
Self-citationTrapping of palindromic ligands within native transthyretin prevents amyloid formation
Kolstoe, S. E., Mangione, P. P., Bellotti, V., Taylor, G. W., Tennent, G. A., Deroo, S., Morrison, A. J., Cobb, A. J. A., Coyne, A. G., McCammon, M. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008255107 · Cited by 68
Wiseman, R. L., Green, N. S., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi050352o · Cited by 65
Self-citationCoelho, T., Chorão, R., Sousa, A., Alves, I. L., Torres, M. F., & Saraiva, M. J. (1996) · Neuromuscular Disorders · doi:10.1016/0960-8966(96)88826-2 · Cited by 61
Blirup-Jensen, S. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.175 · Cited by 48
Hypokalemic periodic paralysis mutations: Confirmation of mutation and analysis of founder effect
Grosson, C. L. S., Esteban‐Pérez, J., McKenna-Yasek, D. M., Gusella, J. F., & Brown, R. H. (1996) · Neuromuscular Disorders · doi:10.1016/0960-8966(95)00018-6 · Cited by 47
Cited by
The amyloid state and its association with protein misfolding diseases.
Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382
The proteostasis network and its decline in ageing
Hipp, M. S., Kasturi, P., & Hartl, F. U. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0101-y · Cited by 1,642
Molecular Chaperone Functions in Protein Folding and Proteostasis
Kim, Y. E., Hipp, M. S., Bracher, A., Hayer-Hartl, M., & Ulrich Hartl, F. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060208-092442 · Cited by 1,475
A new era for understanding amyloid structures and disease
Iadanza, M. G., Jackson, M. P., Hewitt, E. W., Ranson, N. A., & Radford, S. E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0060-8 · Cited by 980
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Self-citation
Metadata
- Authors
- Bulawa, C. E., Connelly, S., DeVit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J., Powers, E. T., Wiseman, R. L., Foss, T. R., Wilson, I. A., Kelly, J. W., & Labaudinière, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-05-29
- Volume
- 109
- Issue
- 24
- Pages
- 9629-9634
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2158907165
- Cited by
- 742
- References
- 61
- FWCI
- 16.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.